October 1, 2019 Bio/Pharma/CRO Lab Top-10 M&A, Partnerships

Thermo Fisher Scientific Enhances Leading Pharma Services Offering by Expanding API Manufacturing Capabilities

Thermo Fisher Scientific Enhances Leading Pharma Services Offering by Expanding API Manufacturing Capabilities Expansion follows the Completion of the Acquisition of GSK Manufacturing Site in Cork, Ireland CORK, Ireland, October 1, 2019 – Thermo Fisher Scientific, the world leader in serving science, announced the expansion of its API manufacturing capabilities following the completion of its... Read more

September 30, 2019 Bio/Pharma/CRO PR/Corporate

Roche presents positive Phase III results for Tecentriq® (atezolizumab) in combination with platinum-based chemotherapy in people with previously untreated advanced bladder cancer

Basel, 30 September 2019 Roche presents positive Phase III results for Tecentriq® (atezolizumab) in combination with platinum-based chemotherapy in people with previously untreated advanced bladder cancer IMvigor130 is the first positive Phase III study of a cancer immunotherapy combination in people with previously untreated advanced bladder cancer Tecentriq combination reduced the risk of disease worsening... Read more

September 30, 2019 Bio/Pharma/CRO Informatics & Software M&A, Partnerships Mass Spectrometry

SCIEX and Protein Metrics Join Forces to Meet Biopharmaceutical Customers’ AI and Automation-driven Data Requirements

Integration to empower fast data processing from all SCIEX high resolution accurate mass platforms as digital transformation of life sciences industry and push towards Precision Medicine continues to drive demand for data September 30, 2019 Framingham, MA — SCIEX a global leader in life science analytical technologies, has announced an extended partnership with Protein Metrics Inc., a premier... Read more

September 27, 2019 Atomic Spectroscopy Bio/Pharma/CRO PR/Corporate

Roche’s Tecentriq in combination with Avastin shows encouraging results in Phase Ib study of people with unresectable hepatocellular carcinoma

Basel, 27 September 2019 Roche’s Tecentriq in combination with Avastin shows encouraging results in Phase Ib study of people with unresectable hepatocellular carcinoma The study showed a confirmed objective response rate of 36% for people treated with the Tecentriq and Avastin combination in unresectable hepatocellular carcinoma who have not received prior systemic therapy The combination... Read more

September 18, 2019 Bio/Pharma/CRO Lab Top-10 Microscopy Product Launch

New Desktop SEM from Thermo Fisher Scientific Helps Manufacturers Improve Quality Control, Production Efficiency and Material Cleanliness

New Desktop SEM from Thermo Fisher Scientific Helps Manufacturers Improve Quality Control, Production Efficiency and Material Cleanliness Easy-to-use Thermo Scientific Phenom ParticleX can characterize particles up to 10 times faster than outsourcing HILLSBORO, Ore., Sept. 18, 2019 /PRNewswire/ — Thermo Fisher Scientific today introduced the Thermo Scientific Phenom ParticleX, a versatile and intuitive desktop scanning electron microscope... Read more

September 12, 2019 Bio/Pharma/CRO

Roche’s satralizumab significantly reduced relapse risk in second positive phase III study for neuromyelitis optica spectrum

Basel, 12 September 2019 Roche’s satralizumab significantly reduced relapse risk in second positive phase III study for neuromyelitis optica spectrum Pivotal phase III SAkuraStar study shows 55% reduction in the risk of relapse for satralizumab monotherapy versus placebo presented at ECTRIMS congress 2019 74% reduction in the risk of relapse for satralizumab monotherapy versus placebo... Read more

September 12, 2019 Bio/Pharma/CRO

Roche’s Tecentriq as a first-line monotherapy helped certain people with advanced non-small cell lung cancer live longer compared with chemotherapy

Basel, 12 September 2019 Roche’s Tecentriq as a first-line monotherapy helped certain people with advanced non-small cell lung cancer live longer compared with chemotherapy Data will be shared with health authorities globally, including the US Food and Drug Administration (FDA) and European Medicines Agency (EMA)Bullet Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive data... Read more

September 2, 2019 Bio/Pharma/CRO PR/Corporate

Positive phase III results show Xofluza reduces risk of developing flu after contact with an infected person by 86%

Basel, 02 September 2019 Positive phase III results show Xofluza reduces risk of developing flu after contact with an infected person by 86% BLOCKSTONE study reaches primary endpoint of fewer people testing positive for flu, with fever and at least one respiratory symptom, when treated with Xofluza versus placebo Xofluza may represent an important and... Read more

September 2, 2019 Bio/Pharma/CRO PR/Corporate

Roche presents positive phase III study results for one-dose Xofluza in children with flu

Basel, 02 September 2019 Roche presents positive phase III study results for one-dose Xofluza in children with flu Phase III MINISTONE-2 data are consistent with known safety profile of Xofluza (baloxavir marboxil) in children and show comparable efficacy to oseltamivir Xofluza was administered as a new one-dose oral suspension, a potentially more convenient treatment option... Read more